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Abstract
 .  .Dehydroepiandrosterone DHEA and its sulfate DHEA-S are the most abundant steroids in humans, and their serum
 .concentrations progressively decrease with age. Although relationships between DHEA -S and many age-related illnesses
have been postulated, the mechanisms for their effects remain unknown, and specific receptors for these molecules have not
 .been identified. In this paper, to investigate the role of DHEA -S in atherogenesis, we studied the proliferation and
 .migration of a rabbit vascular smooth muscle cell line, SM-3, in the presence of DHEA -S . Cellular proliferation was
inhibited by DHEA-S, and to a lesser extent by DHEA. Modified Boyden’s chamber assays revealed that DHEA-S inhibited
the migration of SM-3 cells toward PDGF-BB. In cell attachment assays, DHEA-S inhibited the attachment of SM3 cells to
fibronectin. It was suggested that the inhibitory effect of DHEA-S for SM-3 proliferation and migration was due to the
decreased interaction with fibronectin. Scatchard analysis revealed the presence of two populations of DHEA-S binding
sites in the nuclear fraction, and a smaller number in the cytosolic fraction. Since the dissociation constant of the higher
 .affinity site was similar to the serum DHEA-S concentration in humans K s5.8 mM , this binding site could be functionald
under physiologic conditions. These findings suggest that there may be receptor-mediated anti-atherogenic actions of
DHEA-S. q 1998 Elsevier Science B.V.
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1. Introduction
 .Dehydroepiandrosterone DHEA and its sulfate
 .DHEA-S are the most abundant steroid hormones in
humans, having serum concentrations of the order of
10y8 and 10y6 M, respectively. Serum concentra-
tions peak between 20 and 30 years of age, after
) Corresponding author. Fax: q81-726-83-1801; E-mail:
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which they progressively decrease. For example,
DHEA-S is reduced to about 20% of its peak level by
70 years of age, decreasing further to 5% between 85
w xand 90 years of age 1,2 . This age-dependent decline
has recently been clinically linked to age-related ill-
w xnesses such as ischemic heart disease 3 , harmful
w xchanges in the amount or distribution of body fat 4 ,
the onset of non-insulin-dependent diabetes, and even
w xsome forms of cancer 5 . Such decreases in DHEA
and DHEA-S levels may contribute to carcinogenesis
0925-4439r98r$19.00 q 1998 Elsevier Science B.V. All rights reserved.
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andror age-related degenerative changes, including
atherosclerosis; and consequently, elucidating the ef-
 .  .fect s of DHEA -S on human physiology is of
paramount importance. Unfortunately the biologic
functions and molecular mechanisms of these pre-
dominant steroid hormones have yet to be clarified.
Proliferation and migration of vascular smooth
 .muscle cells SMCs are known to play important
roles in the formation and progression of intimal
thickening in early-phase atherosclerosis and in
w xrestenosis after vascular injury 6 . It is generally
w xknown that sex hormones affect atherogenesis 3,7 .
For example, male gender is an independent cardio-
w xvascular risk factor 8 . In addition, androgens may
directly accelerate atherosclerosis by stimulating the
w xproliferation of vascular SMCs 9 , while estrogens
w xinhibit their proliferation 10 . On the other hand,
 there is evidence that DHEA and DHEA-S DHEA -
..S have anti-atherogenic actions, although it is
thought that they exhibit weak androgenic activity.
For example, dietary supplementation with DHEA
limited the extent of atherosclerosis in rabbits fed
w xcholesterol and subjected to aortic intimal injury 11 ;
in the hypercholesterolemic rabbit model of hetero-
topic cardiac transplantation, DHEA administration
retarded the progression of the associated accelerated
w xform of coronary atherosclerosis 12 . Epidemiologi-
 .cal studies also support the idea that DHEA -S may
have anti-atherogenic actions, in that a correlation
exists between a lower serum concentration of
DHEA-S and a higher rate of cardiovascular events
w x13 . The key to achieving a better understanding of
 .the anti-atherogenic action of DHEA -S is to eluci-
date at what point in atherogenesis they play a critical
 .role. In this study, to investigate the effect s of
 .DHEA -S on atherogenesis, we tested whether
 .DHEA -S directly inhibits the proliferation or migra-
tion of vascular SMCs.
 .The molecular mechanism s of the action of
 .  .DHEA -S is also unknown. DHEA -S may be con-
verted into androstenedione and then into potent an-
w xdrogens andror estrogens in peripheral tissues 14 .
On the other hand, as with other steroid hormones,
 .DHEA -S may act via specific receptors. With this
 .in mind, we performed DHEA -S binding assays in
 .subcellular fractions to assess potential DHEA -S
specific binding sites, and tried to determine whether
 .DHEA -S acts via known steroid hormone receptors.
2. Materials and methods
2.1. Chemicals
We used the following chemicals: DHEA, DHEA-
 .S, testosterone, and estradiol Sigma ; tamoxifen
 . w 3  .xNakarai, Japan ; and 1,2,6,7- H N DHEA and
w 3  .x 1,2,6,7- H N DHEA-S Dupont-New England Nu-
.clear . All other chemicals were commercial products
of reagent grade.
2.2. Cell cultures
SM-3 rabbit aortic SMCs were cultured in Eagle’s
modified essential medium supplemented with 10%
 .calf serum 10% CS-MEM at 378C in an atmosphere
w xof 95% air and 5% CO 15 . For the purpose of2
phenotypic modulation, cells were also cultured un-
 .der conditions of growth-arrest 0.5% CS-MEM for
5–7 days. These conditions have been shown to
restore the contractile apparatus and myosin light
w xchain phosphorylation system 15 . In cases where
various steroidsrchemicals dissolved in ethanol were
added to the culture medium, the ethanol concentra-
tion was maintained at 0.1%.
2.3. Cell proliferation assay
Cell proliferation was assessed with a colorimetric
 .assay kit CellTiter 96 AQueous Assay, Promega
 . using 3- 4,5-dimethylthiazol-2-yl -5- 3-carboxy-
.  .methoxyphenyl -2- 4-sulfophenyl -2H-tetrazolium
and phenazine methosulfate, as substrates. Ab-
sorbance was measured at 490 nm since there is a
linear response between cell number and optical den-
sity at this absorbance. Culture medium was supple-
 .mented with DHEA -S at the concentration of 0.1–
10 mm. In controls, ethanol alone was added to the
culture medium. The culture medium was not changed
until the colorimetric assay.
2.4. Western blot analysis
Cultured SMCs were solubilized with a buffer pH
.8.0 containing 137 mM NaCl, 20 mM Tris–HCl, 1%
NP-40, 10% glycerol, 1 mM PMSF, 10 mgrml apro-
tinin, 1 mgrml leupeptin, and 0.5 mM sodium vana-
 .date. Proteins 15mg were resolved by SDS-PAGE
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in 10 or 12% gels in the buffer system of Laemmli
w x16 , and then transferred electrophoretically to a
 .PVDF membrane Amersham, UK . After performing
immunodetections probed with antibodies, bound an-
tibodies were visualized by an ECL Western blotting
 .system Amersham, UK . The following antibodies
 . were used: anti-a-actin Sigma , anti-a-actin Enzo
.  .Diagnostic , anti-p53 Novocastra, UK , anti-pro-
 . liferating cell nuclear antigen PCNA Signet Labo-
.ratories .
2.5. Adhesion assay
Adhesion studies were performed as described pre-
w xviously 17 . Briefly, a 96-well plate was coated with
 .30 mgrml human fibronectin Sigma , 100 mgrml of
 .bovine collagen type I Chemicon , 20 mgrml of
 .human vitronectin Takara, Japan , or 1 mgrml
 .bovine elastin Elastin products , and blocked with
10 mgrml bovine serum albumin. SM-3 cells were
tripsinized and approximately 2.0=104 cells were
added to each well. After 1 h incubation at 378C, the
cells were washed twice with PBS, fixed in 4%
paraformaldehyde for 10 min, stained with 0.5% tolu-
idine blue and rinsed in water. Cells were solubilized
and quantified using a microtiter plate reader at
595 nm. The experiments described were performed
in quadruplicate and were repeated a minimum of
three times. Mean of the data from experiments are
shown.
2.6. Migration assay
Migration was assayed by modification of the
Boyden’s chamber method using microchemotaxis
 .chambers Neuro Probe and polycarbonate filters
 . w xNecleopore with a pore size of 5.0 mm 18 . The
filters were coated with 20 mgrml fibronectin and
placed between the chambers. Cells were trypsinized
and suspended at a concentration of 5.0 =
105 cellsrml in MEM supplemented with 10% CS.
 .The SMC suspension 50 ml was placed in the upper
chamber, and 25ml of MEM containing human re-
combinant platelet-derived growth factor-BB PDGF-
.  .BB Sigma was placed in the lower chamber. The
chamber was incubated at 378C in 5% CO in air for2
3 h. The filter was removed, and the SMCs which
migrated to the lower side of the filter were fixed in
methanol, stained with Diff-Quik staining solution
 .Kokusai shinyaku, Japan , and counted under micro-
 .scope =100 to quantify SMC migration. Migration
activity was expressed as the mean number of cells
that had migrated per high-power field. Experiments
 .using 20% fatal calf serum FCS , instead of PDGF-
BB, were also performed.
2.7. Preparations of subcellular fractions
Crude nuclear, membrane, and soluble fractions of
SM-3 SMCs were obtained by Hogeboom’s method
w x19 . The soluble fraction was partially concentrated
with a membrane filter Ultrafree-CL plus 10000,
.Millipore, Japan and subjected to Scatchard analysis.
[3 ] [3 ]2.8. H DHEA and H DHEA-S binding assay
w3 x w3 xBinding assays with H DHEA or H DHEA-S
were performed as previously described with slight
w xmodifications 20 . Briefly, fractions of SMCs in
 .TEDGM buffer pH 7.4 containing 50 mM Tris–HCl,
 .1.5 mM EDTA, 0.5 mM DTT, 10% vrv glycerol,
10 mM sodium molybdate, 0.1 mM PMSF, 10 mm
leupeptin, 10 mm pepstatin A, and 10 mgrml apro-
w 3  .xtinin were incubated with 5 nM of 1,2,6,7- H N
 . w 3  .xDHEA 89.2 Cirmmol , or 1,2,6,7- H N DHEA-S
 .92.5 Cirmmol in the presence of various concentra-
tions of unlabeled DHEA or DHEA-S. After adding
hydroxyapatite suspension to obtain a 10% final con-
 .centration wrv and waiting 15 min, the solution
 .was centrifuged 10000=g, 5 min . Resultant pellets
 .were washed three times with PBS pH 7.4 and
extracted with 1 ml of ethanol. The radioactivity in
this extract was measured by a liquid scintillation
counter. Nonspecific binding was measured after
adding 100 mm of unlabeled DHEA or DHEA-S. All
assays were conducted in triplicate.
3. Results
 .Fig. 1 a shows the effect of DHEA-S, at 1 mM,
and 10 mM concentrations, on the proliferation of
SM-3 SMCs. In comparison to control cultures, SMC
proliferation was significantly inhibited by DHEA-S
at 1 and 10 mM. These concentrations of DHEA-S
are similar to the normal serum concentration in adult
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 .Fig. 1. A DHEA-S inhibit the proliferation of the SM-3 smooth
muscle cells. SMC proliferation in the presence of 0 mM closed
.  .  .circle , 1mM open circle , and 10 mM closed square DHEA-S.
 .  .) P -0.05 vs. control 0 mM DHEA-S , t-test. B Inhibition of
the proliferation of SM-3 cells is independent of estrogen action.
SM-3 cells were cultured in the presence of 10 mM DHEA-S with
 .  .closed square or without open circle tamoxifen. Control cul-
tures with 0.1% ethanol are shown by closed circles. Each point
represents the mean and standard deviation of eight assays. There
is a linear relationship between cell number and the optical
density at 490nm under these conditions.
humans. DHEA-S at 0.1 mM did not inhibited the
 .proliferation significantly. Fig. 1 b shows corre-
sponding results for DHEA-S at 10 mM with or
without the presence of the estrogen antagonist ta-
 .moxifen 0.1 mM . The finding that tamoxifen has no
clear effect on proliferation by DHEA-S suggests that
this effect is independent of estrogen action, and that
DHEA-S itself is responsible for this effect i.e., it
.does not occur by DHEA-S conversion to estrogens .
On the other hand, a lesser degree of inhibitory effect
was observed by DHEA at 1 and 10 mM, which is
 .supraphysiological level data not shown . With this
in mind, we further studied the differentiation, migra-
tion and adhesion mainly in the presence of DHEA-S.
PCNA expression during the proliferation phase of
 .  . SMCs is not affected by DHEA -S 10 mM Fig.
 ..2 a . Results of similar experiments also showed that
 .DHEA -S does not induce the expression of p53, a
 .cell-cycle inhibitor data not shown . Moreover, the
expression of smooth muscle a-actin in proliferation
phase SMCs was not affected as shown by im-
  ..munoblot analysis Fig. 2 b . The level of a-actin
expression in SMCs growth-arrested by serum depri-
vation was similar in the presence or absence of
 .   ..10 mM DHEA -S Fig. 2 c . In our studies, these
steroids do not affect expression of phenotypic mark-
ers despite their inhibitory effect on cell growth.
Fig. 2. DHEA-S does not affect the expression of cell-cycle or
 .phenotypic markers of SMCs. A PCNA expression in SM-3
 .  .cells. B a-actin expression in SM-3 cells proliferating phase
 . C a-actin expression in SM-3 cells growth-arrested by serum
.deprivation : lane 1, untreated; lane 2, treated with 10 mM DHEA;
and lane 3, treated with 10 mM DHEA-S.
It is known that smooth muscle cells are induced
w xto migrate toward PDGF-BB 21 . We observed that
DHEA-S inhibited PDGF-induced SM-3 cell migra-
 .tion on fibronectin Fig. 3 . The maximum inhibitory
effect was achieved at 3 mM of DHEA-S. This is
similar level of the physiological serum concentration
of DHEA-S in human. The migration toward FCS
was also inhibited by similar level of DHEA-S data
.not shown . The lesser inhibitory effect was observed
at higher or lower concentration of DHEA-S.
Fig. 3. Migration assay, the modified Boyden’s chamber assay, of
 .the SM-3 cells treated with DHEA-S 1, 3, 10, 30 mM . As
negative control, it was assayed with no PDGF-BB in the lower
chamber. As positive control, experiments with SM-3 cells treated
with 0.1% ethanol were performed. Migration activity was ex-
pressed as the mean number of SM-3 cells, which migrated to the
lower side of the fibronectin coated membrane toward PDGF-BB,
per high-power field. The results were shown as the relative
percent of migrated cell number of control culture. Each bar
represents the mean and standard deviation of quadruplicate
assays. ) P -0.05 vs. positive control, t-test.
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In order to analyze the inhibitory effect of prolifer-
ation and migration of DHEA-S, cell attachment
assays were performed. The number of DHEA-S
treated cells attached to the fibronectin was signifi-
cantly less than the number of untreated cells Fig.
.4 . On the other hand, DHEA-S did not affect the
attachment to other extracellular matrix proteins, i.e.,
collagen type I, elastin, and vitronectin.
As the first step of the study for the molecular
mechanism of DHEA-S effect, we tried to show
 .DHEA -S binding sites in subcellular fractions of
w3 xSM-3 cells. In the binding assay with 5 nM H
DHEA-S, the mean specific binding of soluble, crude
membrane, and nuclear fractions were measured as
0.39, 0.23, and 0.45 pmolrmg, respectively. In con-
w3 xtrast, no specific binding occurred with H DHEA
 .in these fractions. Fig. 5 a shows the Scatchard
w3 xanalysis of H DHEA-S binding in the crude nu-
clear fraction. There are two populations of DHEA-S
binding sites, i.e., high- and low-affinity sites with
 .dissociation constants K of 5.8 mM and 27.7 mM,d
respectively. It should be noted that the K value ofd
the high-affinity site is within the range of serum
concentrations of DHEA-S in adult humans. Corre-
sponding results for crude soluble fractions also
showed high- and low-affinity populations of binding
sites, with the values of K and B for the high-af-d max
finity site being similar to those determined for the
crude nuclear fraction. Similar values were also de-
termined for the crude nuclear fraction of growth-
arrested, partially differentiated SMCs data not
.shown .
 .Fig. 4. Adhesion assay of DHEA-S 10 mM treated SM-3 cells.
As control, untreated SM-3 cells were used. The number of cells
attached to each extracellular matrix components were assessed
by absorbance at 570nm after staining. The results were shown
as the relative percent of attached cell number of control culture.
Each bar represents the mean and standard deviation of quad-
ruplicate assays. ) P -0.05 vs. control, t-test.
 . w3 xFig. 5. A Scatchard analysis of H DHEA-S binding in the
w3 xcrude nuclear fraction of SM-3 cells. Two populations of H
DHEA-S binding sites are shown. High affinity site; K sd
5.8 mM, B s0.5 nmolrmg protein. Low affinity site; K smax d
27.7mM, B s1.8 nmolrmg protein. Each point represents themax
 . w3 xmean value from triplicate experiments. B H DHEA-S bind-
ing in the crude nuclear fraction of SM-3 cells is not inhibited by
the presence of physiologic concentrations of various steroids
testosterone, closed circles; estradiol, open circles; progesterone,
.closed squares; DHEA, open squares . Each point represents the
w3 xmean value from triplicate experiments. Total binding of H
DHEA-S is shown as the relative percent of binding in the
absence of other steroids.
w3 xTo evaluate the ligand specificity of this H
w3 xDHEA-S binding, competitive binding assays of H
DHEA-S were performed in the presence of various
concentrations of unlabeled compounds. Testos-
terone, estradiol, progesterone, or DHEA, at their
physiologic concentrations or greater, did not inhibit
w3 x   ..H DHEA-S binding Fig. 5 b .
4. Discussion
 .Several clinical studies suggest that DHEA -S is
wprotective against many age-related illnesses 3–
x5,22,23 . Experimental studies also support this idea.
For example, DHEA or DHEA-S inhibit the growth
w xof some cell lines 24,25 and prevent some types of
w xchemical carcinogenesis 26 . They also have anti-di-
abetogenic actions, in that DHEA prevents diabetoge-
w xnesis in genetically diabetic mice 27,28 . DHEA
w xinhibits atherogenesis in injured 11 and transplanted
w xvessels 12 . In this study, we focused on the relation-
 .ship between DHEA -S and atherosclerosis, and
demonstrated an inhibitory effect of DHEA-S on
vascular SMC proliferation and migration in vitro.
This result supports previous reports concerning the
 .anti-atherogenic effects of DHEA -S in vivo.
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Although it has been considered that DHEA is the
biological active molecule and DHEA-S is the ‘‘stor-
age form’’ of the hormone, recent studies suggested
DHEA could not act, in some cases, unless metabo-
w xlized by steroid sulfotransferase to DHEA-S 29,30 .
Because our study showed that DHEA had only weak
inhibitory effect for SM-3 cellular proliferation and
there is no binding site of DHEA in these cells, the
w xanti-atherogenic action of DHEA 11,12 may be due
to the conversion of DHEA to DHEA-S in vivo.
Although many reports have shown a beneficial
 .effect of DHEA -S on atherosclerosis in humans and
w x  .laboratory animals 11–13,31 , mechanism s of this
action remains unknown. There are several possible
 .pathways through which DHEA -S may exert its
anti-atherogenic effects. For example, DHEA may
w xprevent platelet aggregation 32 and cholesterol up-
w xtake 33 . One recent report showed that DHEA-S
had a direct effect on the vascular contractility and
w xintracellular calcium responses 34 . The anti-diabetic
 .actions of DHEA -S may contribute to its anti-
atherogenic effects. Although it was reported that
serum lipids and lipoproteins were unchanged during
w xDHEA administration in laboratory animals 11,12 , a
recent pilot study suggested that DHEA supplementa-
tion lowered triglycerides, phospholipid and in-
creased HDL cholesterol levels, and reduced serum
w xlipid peroxidation in older humans 35 . Anti-athero-
 .genic actions of DHEA -S in vivo may be due to the
modification of lipid metabolism in part. On the other
hand, because the formation and progression of inti-
mal thickening is primarily due to accumulation of
SMCs, SMC proliferation and migration are impor-
tant events in atherogenesis. We demonstrated direct
inhibition of vascular SMC proliferation and migra-
 .tion by DHEA -S . It is suggested that these inhibi-
tion may contribute to anti-atherogenic effects in
vivo.
It was reported that fibronectin and vitronectin
w xpromoted migration of SMCs 36,37 . Other extracel-
lular matrix components such as laminin, collagen
and the glycosaminoglycan heparin may have in-
w xhibitory effects on migration 6 . On the other hand,
fibronectin and collagen type I enhance the prolifera-
tion of SMCs, whereas laminin and elastin do not
w xhave such effect 38 . In the present study, we
demonstrated that DHEA-S inhibited the attachment
of SMCs to fibronectin, but not to collagen type I,
vitronectin, or elastin. This result suggests that the
inhibitory effect of DHEA-S for SMC proliferation
and migration is due to the decreased interaction with
fibronectin.
Classic steroid hormones such as estrogen, proges-
terone, androgens, glucocorticoids, and mineralcorti-
w xcoids act via their specific receptors 39 . These
receptors may reside in the cytoplasm or nucleus, and
are intracellular transcription factors that are inactive
in the absence of and active in the presence of
ligands. These receptor genes form a superfamily.
Although many cDNAs of the steroid hormone recep-
 .tor superfamily have been cloned, the receptor s for
DHEA and DHEA-S have not been cloned. Do they
act via specific receptors? Some reports of DHEA or
DHEA-S binding have been published. Binding of
DHEA to whole cell preparations of human fibrob-
w x w xlasts 40 and T lymphocytes 20 , and cytosolic
w x w xbinding in rat liver 41 and mouse melanoma 24
cells have been reported. Binding of DHEA-S in the
w xcytosol of rat liver 42 and in membranes or synapto-
w xsomes 43 from rat brain have also been shown.
However, the functional significance of such binding
sites remain unknown. We can not say that the
binding sites seen in SM-3 cells are specific receptors
for these molecules. In addition, it may be unlikely
that the putative DHEA-S binding protein is similar
to classic steroid hormone receptors, because the Kd
value of DHEA-S binding in SM-3 cells is extremely
higher than that of classic steroid hormone receptors.
The K value of DHEA-S binding is similar tod
serum concentrations of DHEA-S in adult humans. In
addition, it was recently reported that DHEA-S was
transported into hepatocytes by a transporter system
w x44 . This study showed that the K is 17.0 mM andm
V is 3.7 nmolrminrmg protein for the DHEA-Smax
transport. Free DHEA could enter cells by diffusion
and might be converted to DHEA-S by DHEA sulfo-
w xtransferase 45 . High serum level of DHEA-S and
such transportrconversion system may achieve the
sufficient concentration in the cytosol or nucleus for
the specific binding which we have shown, although
we do not know the exact concentration of DHEA-S
in the cytosol or nucleus. Thus, these binding sites
may act functionally under physiologic conditions.
Moreover, two populations of DHEA-S binding sites
may contribute to the inverse bell shape dose re-
sponse of DHEA-S in the inhibition of SMC migra-
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tion. Results of this study suggests that there are
 .specific receptor-mediated actions of DHEA -S .
Another proposed mechanism for the actions of
 . w xDHEA -S is the ’intracrinologic’ mechanism 46 .
 .According to this hypothesis, DHEA -S may act as
precursors of androgens or estrogens in peripheral
tissues. Because it has been reported that androgens
w xstimulate SMC proliferation 9 , and it is known that
male gender is a risk factor for atherosclerosis, andro-
gen receptor-mediated actions are not likely to be
responsible for the inhibitory effect of DHEA-S on
SMC proliferation. On the other hand, estrogens ap-
pear to have anti-atherogenic actions, which leads us
to test whether the actions of DHEA-S are mediated
by the estrogen receptor. However, the inhibitory
effect of DHEA-S on SM-3 cell proliferation was not
blocked by an antagonist of the estrogen receptor.
This suggests that DHEA-S itself is responsible for
the inhibitory effect, i.e., it is not converted to estra-
diol. Although our results suggest specific binding
receptors for DHEA-S exist, further studies, espe-
cially those aimed at receptor cloning, will be needed
to prove this. Moreover, the anti-atherogenic actions
of DHEA-S should be tested in vivo studies.
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